BRAF Mutation Analysis
Colon Cancer, Melanoma, Papillary Thyroid, Non-Small Cell Lung Cancer
Test Codes
BRAF, V600E, Beaker: MBRF
Department
Molecular Pathology
Specimen Collection Criteria
Collect: Paraffin-embedded tissue. A paraffin block must be submitted. (Slides or paraffin shavings are not acceptable.) Submit formalin-fixed, paraffin-embedded block with corresponding H&E slide. Tissue should be well fixed and well processed. Average tissue size 5.0 mm2.
- The specimen must be accompanied by a completed requisition and must contain the patient name, date of birth, collection date, ordering physician, and source of specimen.
Physician Office/Draw Specimen Preparation
Maintain paraffin-embedded tissue at room temperature (20-26°C or 68-78.8°F) until transport.
Preparation for Courier Transport
Transport: Paraffin-embedded tissue, at room temperature (20-26°C or 68-78.8°F).
Rejection Criteria
- Tissue decalcified in agents other than Mol Decal (EDTA).
- Fixatives other than 10% neutral buffered formalin.
- Specimens fixed/processed in alternative fixatives (e.g., alcohol, zinc formalin).
- Improper labeling or inadequate information.
- Less than 10 percent tumor cellularity, at discretion of medical director.
- Poor quality and/or quantity of extracted genomic DNA.
Testing will be cancelled on specimens meeting the above criteria with client notification.
Inpatient Specimen Preparation
Specimens at Royal Oak may be sent to the Surgical Pathology tube station, #201. In-house specimens are also picked up by a Surgical Pathology assistant every hour on the hour.
In-Lab Processing
Maintain specimens at room temperature (20-26°C or 68-78.8°F) until testing.
Storage
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): Indefinitely
Refrigerated (2-8°C or 36-46°F): Unacceptable
Frozen (-20°C/-4°F or below): Unacceptable
Specimen Storage in Department Prior to Disposal:
Room Temperature (20-26°C or 68-78.8°F): 7 days
Laboratory
Royal Oak Clinical Molecular Pathology Laboratory
Performed
Once per week, usually Wednesday.
Results available in 10 business days.
Reference Range
No BRAF V600E mutation detected.
Test Methodology
Tissue sections are reviewed by a pathologist and relevant tumor is selected for analysis. DNA is isolated from the sample and quantified. The DNA is amplified using reagents supplied in a BRAF mutation detection kit (EntroGen, Inc., Tarzana CA). The
samples are analyzed by qualitative real-time PCR. False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue sample.
Interpretation
– Negative; No BRAF V600E mutation detected.
– Positive; BRAF V600 mutation(s) detected.
Clinical Utility
- The BRAF Mutation Analysis Assay provides additional guidance in therapeutic treatment decisions for patients with metastatic colorectal adenocarcinoma, non-small lung cancer (NSCLC), malignant melanoma, papillary thyroid carcinoma, and others.
- Mutations in the BRAF gene, a known downstream signaling molecule in the EGFR signaling pathway, have been described in approximately 15-30% of lung adenocarcinoma, 30-50% of colorectal adenocarcinoma, 37-50% of malignant melanoma, and 40-45% of papillary thyroid carcinoma.
- Recent studies have shown that NSCLC and malignant melanoma positive for the BRAF V600E mutation are responsive to targeted therapeutic agents. In addition, the presence of BRAF V600 mutations may have other prognostic and therapeutic implications in colorectal and papillary thyroid carcinoma.
CPT Codes
81210
Contacts
Molecular Pathology Lab – RO
248-551-0073
Name: Molecular Pathology Lab – RO
Location:
Phone: 248-551-0073
Last Updated
10/30/2023
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.